Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress : vimarsana.com

Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress

Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Texas , United States , Madrid , Spain , Cambridge , Cambridgeshire , United Kingdom , Houston , Michael Lampe , Hans Vitzthum , Greg Dearborn , Sapna Patel , Karin Hellsvik , Nasdaq , Twitter , Therapeutics Inc , Exchange Commission , University Of Texas Md Anderson Cancer Center , Foghorn Therapeutics Inc , Company Annual Report On Form , Therapeutics Announces Clinical Data From Phase , Metastatic Uveal Melanoma , Expansion Study , Metastatic Uveal , Cancer Center , Gene Traffic , Annual Report , Foghorn Therapeutics , Lifesci Advisors ,